[A20-09] Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 04.05.2020
Project no.:
A20-09
Commission:
Commission awarded on 03.02.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults with type 2 diabetes mellitus; monotherapy for patients in whom diet and exercise alone do not provide sufficient glycaemic control and for whom metformin is considered inappropriate due to intolerance or contraindications; combination therapy for patients in whom diet and exercise and the treatment with other blood-glucose lowering drugs do not provide sufficient glycaemic control
Combination therapy for patients in whom diet and exercise and treatment with short-acting insulin (with or without another blood-glucose lowering drug) do not provide sufficient glycaemic control: hint of considerable added benefit if the treatment goal is a not near-normal blood glucose level. All other therapeutic indications and goals: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-07 | Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A23-28 | Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V | Commission completed |